GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » Earnings per Share (Diluted)

Austar Lifesciences (HKSE:06118) Earnings per Share (Diluted) : HK$-0.24 (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences Earnings per Share (Diluted)?

Austar Lifesciences's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was HK$-0.15. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.24.

Austar Lifesciences's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.24.

Austar Lifesciences's EPS without NRI for the six months ended in Dec. 2023 was HK$0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.02.

During the past 12 months, Austar Lifesciences's average EPS without NRIGrowth Rate was -109.60% per year.

During the past 11 years, Austar Lifesciences's highest 3-Year average EPS without NRI Growth Rate was 237.50% per year. The lowest was -8.00% per year. And the median was 105.80% per year.


Austar Lifesciences Earnings per Share (Diluted) Historical Data

The historical data trend for Austar Lifesciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences Earnings per Share (Diluted) Chart

Austar Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.07 0.66 0.19 -0.24

Austar Lifesciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.11 0.09 -0.09 -0.15

Competitive Comparison of Austar Lifesciences's Earnings per Share (Diluted)

For the Medical Devices subindustry, Austar Lifesciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's PE Ratio falls into.



Austar Lifesciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Austar Lifesciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-124.114-0)/512.582
=-0.24

Austar Lifesciences's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (Q: Dec. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-80.424-0)/512.582
=-0.16

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Austar Lifesciences  (HKSE:06118) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Austar Lifesciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Austar Lifesciences (HKSE:06118) Business Description

Traded in Other Exchanges
Address
No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Austar Lifesciences (HKSE:06118) Headlines

No Headlines